US · ORGO · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Organogenesis Holdings Inc. (ORGO) intrinsic value and stock valuation
$0.77as of 2026-11-21 · Mkt cap 239.33M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Organogenesis Holdings Inc. DCF and intrinsic value
InvestorsCraft values ORGO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ORGO’s statements →
Organogenesis Holdings Inc. Graham Number
Graham Number: $4.74d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $563M | $482M | $433.1M | $450.9M | $467.4M |
| Operating income | $55.9M | -$-1.28M | $12.5M | $22.3M | $72.2M |
| Net income | $37M | $860K | $4.95M | $15.5M | $94.2M |
| EPSd | $284.3K | $6.53K | $37.3K | $117.3K | $704.8K |
| Operating cash flow | -$-10.31M | $14.2M | $30.9M | $24.9M | $62M |
| Capital expenditure | -$-14.15M | -$-10.03M | -$-24.36M | -$-33.9M | -$-31.22M |
| Free cash flow | -$-24.46M | $4.18M | $6.55M | -$-9.04M | $30.8M |
| Total assets | $598.7M | $497.9M | $460M | $449.4M | $443.3M |
| Total debt | $132.8M | $43.3M | $119.4M | $123.8M | $132.3M |
| Net debt | $39.2M | -$-92.26M | $15M | $21.3M | $18.4M |
| Total equity | $433.9M | $385.3M | $278.7M | $265.7M | $241.3M |
| Cash and short-term investments | $93.7M | $135.6M | $104.3M | $102.5M | $113.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $563M | $482M | $433.1M | $450.9M | $467.4M |
| Cost of revenue | $137.5M | $115.7M | $106.5M | $105M | $114.2M |
| Gross profit | $425.5M | $366.3M | $326.7M | $345.9M | $353.2M |
| Research and development expenses | $44.5M | $50.3M | $44.4M | $39.8M | $30.7M |
| Selling, general and administrative expenses | $326.2M | $294.5M | $269.8M | $283.8M | $250.2M |
| Other expenses | -$-1.14M | $22.8M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $369.6M | $367.6M | $314.1M | $323.6M | $280.9M |
| Cost and expenses | $507.2M | $483.3M | $420.6M | $428.6M | $395.1M |
| Interest income | $2.28M | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $1.54M | $2.19M | $2.01M | $7.24M |
| Depreciation and amortization | $26.9M | $17M | $23.5M | $18M | $16.7M |
| Ebitda | $73.9M | $15.8M | $36M | $40.3M | $87M |
| Operating income | $55.9M | -$-1.28M | $12.5M | $22.3M | $72.2M |
| Total other income/expenses, net | -$-8.9M | -$-1.52M | -$-2.13M | -$-2.02M | -$-9.13M |
| Income before tax | $47M | -$-2.81M | $10.4M | $20.3M | $63.1M |
| Income tax expense | $9.94M | -$-3.67M | $5.45M | $4.75M | -$-31.12M |
| Net income | $37M | $860K | $4.95M | $15.5M | $94.2M |
| Weighted average shares outstanding | $126.7M | $131.7M | $131.2M | $130.1M | $128.3M |
| Weighted average diluted shares outstanding | $130.3M | $131.7M | $132.8M | $132.4M | $133.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $93.7M | $135.6M | $104.3M | $102.5M | $113.9M |
| Net receivables | $217.5M | $109.9M | $82M | $89.5M | $82.5M |
| Inventory | $29.6M | $26.2M | $28.3M | $24.8M | $25M |
| Total current assets | $362.2M | $285.9M | $225M | $222.6M | $227M |
| Property, plant and equipment, net | $159.5M | $126.2M | $156.4M | $145.7M | $128.3M |
| Goodwill and intangible assets | $37.9M | $41.2M | $44.6M | $49.6M | $54.5M |
| Long-term investments | $0.00 | $0.00 | $15.9M | $0.00 | $0.00 |
| Total non-current assets | $236.5M | $211.9M | $235M | $226.8M | $216.3M |
| Total assets | $598.7M | $497.9M | $460M | $449.4M | $443.3M |
| Accounts payable | $32M | $28.9M | $30.7M | $32.3M | $29.3M |
| Short-term debt | $18.6M | $9.11M | $19.7M | $16.3M | $14.6M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $100.1M | $77.5M | $80.5M | $75M | $82.7M |
| Long-term debt | $114.2M | $34.2M | $99.6M | $107.6M | $117.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $64.7M | $35.1M | $100.9M | $108.7M | $119.2M |
| Capital lease obligations | $63.5M | $43.3M | $53.1M | $53M | $58.9M |
| Total liabilities | $164.8M | $112.6M | $181.4M | $183.7M | $201.9M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-3.08M | -$-40.11M | -$-40.97M | -$-45.3M | -$-60.83M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $433.9M | $385.3M | $278.7M | $265.7M | $241.3M |
| Total investments | $0.00 | $0.00 | $15.9M | $0.00 | $0.00 |
| Total debt | $132.8M | $43.3M | $119.4M | $123.8M | $132.3M |
| Net debt | $39.2M | -$-92.26M | $15M | $21.3M | $18.4M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $37M | $860K | $4.95M | $15.5M | $94.9M |
| Depreciation and amortization | $26.9M | $17M | $23.5M | $10.7M | $16.7M |
| Stock-based compensation | $13.3M | $10.6M | $9M | $6.55M | $3.86M |
| Change in working capital | -$-132.38M | -$-48.89M | -$-18.07M | -$-34.08M | -$-39.29M |
| Accounts receivable | -$-115.8M | -$-31.8M | $5.54M | -$-8.77M | -$-30.23M |
| Inventory | -$-17.91M | -$-6.2M | $6.58M | -$-9.41M | -$-9.3M |
| Accounts payable | -$-530K | -$-2.37M | -$-110K | $3.26M | $3.85M |
| Net cash provided by operating activities | -$-10.31M | $14.2M | $30.9M | $24.9M | $62M |
| Investments in property, plant and equipment | -$-14.15M | -$-10.03M | -$-24.36M | -$-33.9M | -$-31.22M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-14.15M | -$-10.03M | -$-24.36M | -$-33.9M | -$-31.22M |
| Common stock issued | $160K | $0.00 | $0.00 | $0.00 | $2.2M |
| Common stock repurchased | $0.00 | -$-25.48M | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | -$-1.8M | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-17.36M | $27.6M | -$-5.5M | -$-2.2M | -$-1.04M |
| Net change in cash | -$-41.82M | $31.8M | $1.05M | -$-11.24M | $29.7M |
| Cash at end of period | $94.3M | $136.2M | $104.3M | $103.3M | $114.5M |
| Operating cash flow | -$-10.31M | $14.2M | $30.9M | $24.9M | $62M |
| Capital expenditure | -$-14.15M | -$-10.03M | -$-24.36M | -$-33.9M | -$-31.22M |
| Free cash flow | -$-24.46M | $4.18M | $6.55M | -$-9.04M | $30.8M |
Line items
Line items
Line items
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
- CEO
- Gary S. Gillheeney
- Employees
- 854
- Beta
- 1.33
Explore
Frequently asked questions
What is the intrinsic value of Organogenesis Holdings Inc. (ORGO)?
InvestorsCraft does not currently publish an intrinsic value for ORGO. How the IC value is calculated.
Is ORGO undervalued?
InvestorsCraft does not publish an undervaluation signal for ORGO at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.